Labcorp Holdings Inc. (NYSE:LH) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Labcorp Holdings Inc. (NYSE:LH) have been assigned an average rating of “Moderate Buy” from the eleven research firms that are covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $314.40.

LH has been the topic of a number of recent research reports. Bank of America lifted their target price on Labcorp from $300.00 to $320.00 and gave the stock a “buy” rating in a research report on Monday, July 13th. Robert W. Baird raised their price objective on Labcorp from $335.00 to $338.00 and gave the stock an “outperform” rating in a research report on Monday, July 13th. Weiss Ratings reissued a “buy (b-)” rating on shares of Labcorp in a report on Friday, May 8th. Wall Street Zen upgraded Labcorp from a “hold” rating to a “buy” rating in a research report on Sunday, July 12th. Finally, Evercore restated an “outperform” rating and issued a $300.00 target price on shares of Labcorp in a research note on Wednesday, April 8th.

Insider Activity

In other news, EVP Kathryn W. Kyle sold 762 shares of Labcorp stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $263.89, for a total transaction of $201,084.18. Following the sale, the executive vice president directly owned 3,813 shares in the company, valued at approximately $1,006,212.57. The trade was a 16.66% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Adam H. Schechter sold 5,903 shares of the company’s stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $254.50, for a total transaction of $1,502,313.50. Following the completion of the sale, the chief executive officer directly owned 107,234 shares in the company, valued at approximately $27,291,053. The trade was a 5.22% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 6,991 shares of company stock worth $1,796,696. 0.84% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Labcorp

A number of institutional investors have recently added to or reduced their stakes in LH. Thurston Springer Miller Herd & Titak Inc. bought a new position in shares of Labcorp during the 4th quarter worth approximately $26,000. Hilton Head Capital Partners LLC bought a new stake in Labcorp in the fourth quarter valued at $27,000. JPL Wealth Management LLC bought a new stake in Labcorp in the third quarter valued at $28,000. Eagle Bay Advisors LLC acquired a new position in Labcorp during the fourth quarter worth $29,000. Finally, DV Equities LLC acquired a new position in Labcorp during the fourth quarter worth $29,000. 95.94% of the stock is owned by institutional investors and hedge funds.

Labcorp Price Performance

Shares of Labcorp stock opened at $283.63 on Friday. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.73 and a quick ratio of 1.54. Labcorp has a fifty-two week low of $241.81 and a fifty-two week high of $293.72. The firm has a fifty day moving average price of $266.22 and a two-hundred day moving average price of $267.91. The company has a market cap of $23.26 billion, a PE ratio of 25.12, a price-to-earnings-growth ratio of 1.87 and a beta of 0.89.

Labcorp (NYSE:LH) last posted its quarterly earnings results on Thursday, April 30th. The medical research company reported $4.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.09 by $0.16. The company had revenue of $3.54 billion for the quarter, compared to analyst estimates of $3.51 billion. Labcorp had a net margin of 6.66% and a return on equity of 16.29%. The business’s quarterly revenue was up 5.8% on a year-over-year basis. During the same period last year, the business posted $3.84 EPS. Labcorp has set its FY 2026 guidance at 17.700-18.350 EPS. Analysts expect that Labcorp will post 18 EPS for the current year.

Labcorp Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 11th. Shareholders of record on Friday, August 28th will be issued a $0.72 dividend. This represents a $2.88 annualized dividend and a yield of 1.0%. The ex-dividend date of this dividend is Friday, August 28th. Labcorp’s payout ratio is 25.51%.

Labcorp Company Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.